Letters to the Editor

Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia

Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Department of Leukemia, The University of Texas MD Anderson Cancer Center
Haematologica Early view Mar 26, 2026 https://doi.org/10.3324/haematol.2025.289318